Loading
Treatment of Major Depression · Journal article
Frontiers in Physiology · August 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes emerging preclinical and preliminary clinical evidence on propofol as a potential antidepressant agent. The source acknowledges that clinical data come exclusively from small open-label studies without controlled comparators, and major questions about dosing, tolerance, safety, and implementation remain unresolved; propofol is positioned as a mechanistically interesting candidate for future investigation rather than an established treatment.
Narrative review. Patients with treatment-resistant depression (from cited open-label studies; not enrolled in this review).
Preliminary open-label studies suggest propofol may produce dose-dependent mood-elevating effects in treatment-resistant depression Proposed mechanisms include GABA-A receptor modulation, dopamine transporter inhibition, BDNF/TrkB signaling, and network reorganization of default mode network and sleep architecture Propofol compared with ketamine offers distinct receptor targets and safety profile but efficacy profiles remain to be established in controlled trials
Long-term safety profile in psychiatric use unknown; source notes this as major unresolved challenge Propofol compared with ketamine offers distinct receptor targets and safety profile but efficacy profiles remain to be established in controlled trials
Clinicians should view propofol as a mechanistically intriguing but early-stage research candidate; the evidence does not yet support clinical use. Controlled trials with adequate sample sizes, blinding, and safety monitoring are necessary before any therapeutic role can be established.
A narrative review synthesizing preliminary open-label clinical evidence and putative mechanisms without new empirical data; the source itself acknowledges small sample sizes, lack of controlled trials, and unresolved safety and dosing questions, positioning propofol as a candidate for future study rather than an established therapeutic.
As stated by the source record.
Clinicians should view propofol as a mechanistically intriguing but early-stage research candidate; the evidence does not yet support clinical use. Controlled trials with adequate sample sizes, blinding, and safety monitoring are necessary before any therapeutic role can be established.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Propofol, one of the most widely used intravenous anesthetics, is undergoing a transformative identity shift from a purely surgical agent to a potential therapeutic tool for neuropsychiatric disorders. This review synthesizes current evidence on the emerging field of propofol therapeutics, with a focus on its rapid antidepressant, anti-anhedonia, and anxiolytic effects. We first examine preliminary clinical evidence from open-label studies suggesting that propofol may produce dose-dependent mood-elevating effects in treatment-resistant depression; however, this evidence remains limited by small sample sizes and lack of large controlled trials. Next, we explore putative mechanisms, including GABA A receptor modulation, dopamine transporter inhibition, BDNF/TrkB signaling, and network-level reorganization of the default mode network and sleep architecture. We then compare propofol with other anesthetic agents possessing antidepressant properties, particularly ketamine, highlighting their distinct receptor targets, efficacy profiles, and safety considerations. Finally, we discuss major challenges including optimal dosing strategies, tolerance with repeated administration, long-term safety concerns, and implementation barriers. Despite these challenges, propofol represents a promising candidate for anesthetic repurposing in psychiatry, offering a mechanistically distinct alternative to ketamine that targets both GABAergic and dopaminergic systems with a well-established clinical safety profile for surgical anesthesia.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.